Vigil Neuroscience Inc (VIGL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vigil Neuroscience Inc (VIGL) has a cash flow conversion efficiency ratio of -0.496x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.48 Million) by net assets ($41.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vigil Neuroscience Inc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Vigil Neuroscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Vigil Neuroscience Inc debt and liabilities for a breakdown of total debt and financial obligations.
Vigil Neuroscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vigil Neuroscience Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Candel Therapeutics Inc
NASDAQ:CADL
|
-0.128x |
|
Tsogo Sun
JSE:TSG
|
0.196x |
|
Gospell Digital Technology Co Ltd
SHE:002848
|
-0.071x |
|
DAKOTA GOLD CORP. DL-001
F:RR6
|
N/A |
|
E. W. Scripps Co Class A
NASDAQ:SSP
|
0.036x |
|
GEM Services Inc
TW:6525
|
0.071x |
|
EVN Finance JSC
VN:EVF
|
-0.339x |
|
TAIDOC TECHNOLOGY CORP
TW:4736
|
0.041x |
Annual Cash Flow Conversion Efficiency for Vigil Neuroscience Inc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Vigil Neuroscience Inc from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see Vigil Neuroscience Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $71.64 Million | $-51.22 Million | -0.715x | -18.14% |
| 2023-12-31 | $116.25 Million | $-70.36 Million | -0.605x | -75.66% |
| 2022-12-31 | $189.08 Million | $-65.15 Million | -0.345x | -160.81% |
| 2021-12-31 | $-69.44 Million | $-39.35 Million | 0.567x | +209.37% |
| 2020-12-31 | $-28.28 Million | $-5.18 Million | 0.183x | -- |
About Vigil Neuroscience Inc
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells… Read more